Publications by authors named "Ziyang Mao"
Background: Patients with non-small cell lung cancer (NSCLC) with liver metastasis have a poor prognosis, and there are no reliable biomarkers for predicting disease progression. Currently, no recognized and reliable prediction model exists to anticipate liver metastasis in NSCLC, nor have the risk factors influencing its onset time been thoroughly explored.
Methods: This study conducted a retrospective analysis of 434 NSCLC patients from two hospitals to assess the association between the risk and timing of liver metastasis, as well as several variables.
Article Synopsis
- Checkpoint inhibitor pneumonitis (CIP) is a significant immune-related side effect of immunotherapy, and current methods for predicting it are inadequate.
- A study analyzed data from 547 patients to identify independent risk factors for CIP and developed two nomograms to predict CIP risk (one for any grade and another for grade ≥2).
- The nomograms demonstrated strong predictive accuracy, with high C indexes in both training and validation cohorts, making them potentially useful tools for assessing individual patient risk for developing CIP.
Background: Checkpoint inhibitor pneumonitis (CIP) that does not respond to corticosteroids is termed steroid-refractory CIP. We aimed to find risk factors of steroid-refractory CIP and evaluate the management strategies of immunomodulators (IMs).
Methods: Patients with CIP were identified between August 2019 and August 2022 retrospectively.
Objective: Besides breast and gastric cancer, amplification/mutation are also found in lung adenocarcinoma (LUAD). However, the correlation between variations and the phenotype of immunogenicity and tumor immune microenvironment (TIME) in LUAD compared with breast and gastric cancer has yet to be fully elucidated.
Methods: We integrated public databases (discovery set) and internal data (validated set) of 288 patients representing three distinct -altered tumors.
Introduction: Checkpoint inhibitor pneumonitis (CIP) is a common serious adverse event caused by immune checkpoint inhibitors (ICIs), and severe CIP can be life-threatening. We aimed to investigate the role of peripheral blood cells in diagnosis, prediction, and prognosis evaluation for all and severe CIP.
Materials And Methods: Patients with lung cancer receiving ICIs were enrolled in this retrospective study.
Objectives: Checkpoint inhibitors pneumonitis (CIP) is one of the most lethal adverse events in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Currently, there is no recognized and effective predictive model to predict CIP in NSCLC.
Materials And Methods: This study retrospectively analyzed 460 NSCLC patients who were first treated with ICIs.
Background: Drug-drug interactions (DDIs) pose new challenges beyond traditional pharmacodynamics in the context of optimizing the treatment options with immune checkpoint inhibitors (ICIs). To alleviate cancer-related pain, analgesics are of absolute vital importance as chronic medications used by cancer patients. However, the possible outcome of ICI treatment concomitant with analgesics remains unclear.
View Article and Find Full Text PDFTo compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without mutations or fusions. A network meta-analysis was conducted to synthesize relative treatment outcomes. Chemo + ICIs is superior to Chemo + Bev in both overall survival (hazard ratio: 0.
View Article and Find Full Text PDFBackground: Immune-based combination therapies have revolutionized the first-line treatment for advanced non-small cell lung cancer (NSCLC). However, for the efficacy and safety, the best treatment option is still uncertain.
Methods: We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) to evaluate first-line immune-based combination therapies for advanced NSCLC.
Background: Nivolumab + ipilimumab + two cycles chemotherapy (N-I + chemo, intensive immunotherapy but chemo-light) and pembrolizumab + chemotherapy (Pem + chemo) were both recommended as first-line treatment for metastatic non-small cell lung carcinoma (NSCLC) patients. We conducted this indirect comparison to compare the efficacy of and safety between these two treatments for providing reference for decision making.
Methods: Relevant databases were searched for eligible trials.
Objective: The correlation between immune-related adverse events (irAEs) and prognosis remains controversial in advanced non-small cell lung cancer (NSCLC). The aim of this study was to systematically evaluate the effect of irAEs, especially checkpoint inhibitor pneumonitis (CIP), on the survival and treatment response in advanced NSCLC.
Methods: The primary outcomes were overall survival (OS) and objective response rate (ORR).